{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:40:54Z","timestamp":1794552054796,"version":"4.9.1"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1038\/s41587-022-01294-2","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T12:02:46Z","timestamp":1652097766000},"page":"840-854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":832,"title":["The clinical progress of mRNA vaccines and immunotherapies"],"prefix":"10.1038","volume":"40","author":[{"given":"Ann J.","family":"Barbier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9826-5976","authenticated-orcid":false,"given":"Allen Yujie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5409-7480","authenticated-orcid":false,"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wooster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5629-4798","authenticated-orcid":false,"given":"Daniel G.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"1294_CR1","unstructured":"Moderna. Moderna\u2019s Work on a Potential Vaccine Against COVID-19 https:\/\/www.modernatx.com\/modernas-work-potential-vaccine-against-covid-19 (2020)."},{"key":"1294_CR2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567\u2013571 (2020).","journal-title":"Nature"},{"key":"1294_CR3","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1690918","volume":"247","author":"JA Wolff","year":"1990","unstructured":"Wolff, J. A. et al. Direct gene transfer into mouse muscle in vivo. Science 247, 1465\u20131468 (1990).","journal-title":"Science"},{"key":"1294_CR4","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nrg2432","volume":"9","author":"MA Kutzler","year":"2008","unstructured":"Kutzler, M. A. & Weiner, D. B. DNA vaccines: ready for prime time? Nat. Rev. Genet. 9, 776\u2013788 (2008).","journal-title":"Nat. Rev. Genet."},{"key":"1294_CR5","first-page":"1","volume":"96","author":"R Cross","year":"2018","unstructured":"Cross, R. Can mRNA disrupt the drug industry? Chem. Eng. News 96, 1\u201314 (2018).","journal-title":"Chem. Eng. News"},{"key":"1294_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-1804-8","volume":"17","author":"L Van Hoecke","year":"2019","unstructured":"Van Hoecke, L. & Roose, K. How mRNA therapeutics are entering the monoclonal antibody field. J. Transl. Med. 17, 54 (2019).","journal-title":"J. Transl. Med."},{"key":"1294_CR7","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","volume":"27","author":"G Maruggi","year":"2019","unstructured":"Maruggi, G., Zhang, C., Li, J., Ulmer, J. B. & Yu, D. mRNA as a transformative technology for vaccine development to control infectious diseases. Mol. Ther. 27, 757\u2013772 (2019).","journal-title":"Mol. Ther."},{"key":"1294_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00018-018-2935-4","volume":"76","author":"T Schlake","year":"2019","unstructured":"Schlake, T., Thess, A., Thran, M. & Jordan, I. mRNA as novel technology for passive immunotherapy. Cell. Mol. Life Sci. 76, 301\u2013328 (2019).","journal-title":"Cell. Mol. Life Sci."},{"key":"1294_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0159-8","volume":"5","author":"NAC Jackson","year":"2020","unstructured":"Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S. & DeRosa, F. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines 5, 11 (2020).","journal-title":"NPJ Vaccines"},{"key":"1294_CR10","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","volume":"27","author":"PS Kowalski","year":"2019","unstructured":"Kowalski, P. S., Rudra, A., Miao, L. & Anderson, D. G. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol. Ther. 27, 710\u2013728 (2019).","journal-title":"Mol. Ther."},{"key":"1294_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","volume":"8","author":"P Colella","year":"2018","unstructured":"Colella, P., Ronzitti, G. & Mingozzi, F. Emerging issues in AAV-mediated in vivo gene therapy. Mol. Ther. Methods Clin. Dev. 8, 87\u2013104 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1294_CR12","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","volume":"26","author":"S Sabnis","year":"2018","unstructured":"Sabnis, S. et al. A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol. Ther. 26, 1509\u20131519 (2018).","journal-title":"Mol. Ther."},{"key":"1294_CR13","doi-asserted-by":"publisher","first-page":"E4133","DOI":"10.1073\/pnas.1600299113","volume":"113","author":"JS Chahal","year":"2016","unstructured":"Chahal, J. S. et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc. Natl Acad. Sci. USA 113, E4133\u20134142 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1294_CR14","doi-asserted-by":"publisher","first-page":"282","DOI":"10.4049\/immunohorizons.1900029","volume":"3","author":"G Besin","year":"2019","unstructured":"Besin, G. et al. Accelerated blood clearance of lipid nanoparticles entails a biphasic humoral response of B-1 followed by B-2 lymphocytes to distinct antigenic moieties. Immunohorizons 3, 282\u2013293 (2019).","journal-title":"Immunohorizons"},{"key":"1294_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","volume":"585","author":"U Sahin","year":"2020","unstructured":"Sahin, U. et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 585, 107\u2013112 (2020).","journal-title":"Nature"},{"key":"1294_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11\u201321 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1294_CR17","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Kariko","year":"2008","unstructured":"Kariko, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833\u20131840 (2008).","journal-title":"Mol. Ther."},{"key":"1294_CR18","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/mt.2015.103","volume":"23","author":"A Thess","year":"2015","unstructured":"Thess, A. et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol. Ther. 23, 1456\u20131464 (2015).","journal-title":"Mol. Ther."},{"key":"1294_CR19","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/gt.2017.5","volume":"24","author":"S Guan","year":"2017","unstructured":"Guan, S. & Rosenecker, J. Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther. 24, 133\u2013143 (2017).","journal-title":"Gene Ther."},{"key":"1294_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jconrel.2015.12.032","volume":"240","author":"KJ Kauffman","year":"2016","unstructured":"Kauffman, K. J., Webber, M. J. & Anderson, D. G. Materials for non-viral intracellular delivery of messenger RNA therapeutics. J. Control. Release 240, 227\u2013234 (2016).","journal-title":"J. Control. Release"},{"key":"1294_CR21","doi-asserted-by":"crossref","unstructured":"Dorrie, J., Schaft, N., Schuler, G. & Schuler-Thurner, B. Therapeutic cancer vaccination with ex vivo RNA-transfected dendritic cells\u2014an update. Pharmaceutics 12, 92 (2020).","DOI":"10.3390\/pharmaceutics12020092"},{"key":"1294_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines\u2014a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1294_CR23","doi-asserted-by":"publisher","first-page":"17056","DOI":"10.1038\/natrevmats.2017.56","volume":"2","author":"KA Hajj","year":"2017","unstructured":"Hajj, K. A. & Whitehead, K. A. Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat. Rev. Mater. 2, 17056 (2017).","journal-title":"Nat. Rev. Mater."},{"key":"1294_CR24","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin, U., Kariko, K. & Tureci, O. mRNA-based therapeutics\u2014developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759\u2013780 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1294_CR25","doi-asserted-by":"crossref","unstructured":"Weng, Y. et al. The challenge and prospect of mRNA therapeutics landscape. Biotechnol. Adv. 40, 107534 (2020).","DOI":"10.1016\/j.biotechadv.2020.107534"},{"key":"1294_CR26","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","volume":"10","author":"C Zhang","year":"2019","unstructured":"Zhang, C., Maruggi, G., Shan, H. & Li, J. Advances in mRNA vaccines for infectious diseases. Front. Immunol. 10, 594 (2019).","journal-title":"Front. Immunol."},{"key":"1294_CR27","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1159\/000494034","volume":"10","author":"M Tatematsu","year":"2018","unstructured":"Tatematsu, M., Funami, K., Seya, T. & Matsumoto, M. Extracellular RNA sensing by pattern recognition receptors. J. Innate Immun. 10, 398\u2013406 (2018).","journal-title":"J. Innate Immun."},{"key":"1294_CR28","doi-asserted-by":"publisher","first-page":"1796002","DOI":"10.1080\/2162402X.2020.1796002","volume":"9","author":"G Frega","year":"2020","unstructured":"Frega, G. et al. Trial Watch: experimental TLR7\/TLR8 agonists for oncological indications. Oncoimmunology 9, 1796002 (2020).","journal-title":"Oncoimmunology"},{"key":"1294_CR29","unstructured":"CureVac. CureVac Provides Update on Phase 2b\/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV https:\/\/www.curevac.com\/en\/2021\/06\/16\/curevac-provides-update-on-phase-2b-3-trial-of-first-generation-covid-19-vaccine-candidate-cvncov\/ (2021)."},{"key":"1294_CR30","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1126\/science.372.6549.1381","volume":"372","author":"J Cohen","year":"2021","unstructured":"Cohen, J. What went wrong with CureVac\u2019s mRNA vaccine? Science 372, 1381 (2021).","journal-title":"Science"},{"key":"1294_CR31","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1126\/science.abc4776","volume":"369","author":"A Chandrashekar","year":"2020","unstructured":"Chandrashekar, A. et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 369, 812\u2013817 (2020).","journal-title":"Science"},{"key":"1294_CR32","doi-asserted-by":"crossref","unstructured":"Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806\u2013811 (2020).","DOI":"10.1126\/science.abc6284"},{"key":"1294_CR33","unstructured":"BioNTech. Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19 https:\/\/investors.biontech.de\/node\/8926\/pdf (2020)."},{"key":"1294_CR34","unstructured":"Moderna. U.S. CDC Advisory Committee on Immunization Practices Recommends Vaccination with Moderna\u2019s COVID-19 Vaccine for Persons 18 Years and Older https:\/\/investors.modernatx.com\/news\/news-details\/2020\/U.S.-CDC-Advisory-Committee-on-Immunization-Practices-Recommends-Vaccination-with-Modernas-COVID-19-Vaccine-for-Persons-18-Years-and-Older-12-19-2020\/default.aspx (2020)."},{"key":"1294_CR35","unstructured":"CureVac. CureVac Receives Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate https:\/\/www.curevac.com\/wp-content\/uploads\/2020\/08\/20200617_PR_CureVac_Approval_Phase1_EN_final.pdf?x37733 (2020)."},{"key":"1294_CR36","unstructured":"Arcturus. Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1\/2 Study Results for both Single Shot and Prime\u2013Boost Regimens, and up to $220 Million in Additional Financial Commitments from Singapore https:\/\/ir.arcturusrx.com\/node\/10176\/pdf (2020)."},{"key":"1294_CR37","unstructured":"Translate Bio. Sanofi Pasteur and Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19 https:\/\/investors.translate.bio\/node\/7396\/pdf (2020)."},{"key":"1294_CR38","unstructured":"Moderna, Inc. United States Securities and Exchange Commission Form 10-K (2020)."},{"key":"1294_CR39","doi-asserted-by":"publisher","first-page":"583077","DOI":"10.3389\/fimmu.2020.583077","volume":"11","author":"M Brisse","year":"2020","unstructured":"Brisse, M., Vrba, S. M., Kirk, N., Liang, Y. & Ly, H. Emerging concepts and technologies in vaccine development. Front. Immunol. 11, 583077 (2020).","journal-title":"Front. Immunol."},{"key":"1294_CR40","unstructured":"Moderna. Moderna Announces Progress Across Broad Portfolio and all Three Clinical Stage Therapeutic Areas at 2020 R&D Day https:\/\/investors.modernatx.com\/node\/9896\/pdf (2020)."},{"key":"1294_CR41","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.vaccine.2020.12.070","volume":"39","author":"C Aldrich","year":"2021","unstructured":"Aldrich, C. et al. Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial. Vaccine 39, 1310\u20131318 (2021).","journal-title":"Vaccine"},{"key":"1294_CR42","doi-asserted-by":"crossref","unstructured":"Buschmann, M. D. et al. Nanomaterial delivery systems for mRNA vaccines. Vaccines 9, 65 (2021).","DOI":"10.3390\/vaccines9010065"},{"key":"1294_CR43","doi-asserted-by":"publisher","first-page":"e1800376","DOI":"10.1002\/biot.201970055","volume":"14","author":"Z Kis","year":"2019","unstructured":"Kis, Z., Shattock, R., Shah, N. & Kontoravdi, C. Emerging technologies for low-cost, rapid vaccine manufacture. Biotechnol. J. 14, e1800376 (2019).","journal-title":"Biotechnol. J."},{"key":"1294_CR44","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","volume":"9","author":"S Rauch","year":"2018","unstructured":"Rauch, S., Jasny, E., Schmidt, K. E. & Petsch, B. New vaccine technologies to combat outbreak situations. Front. Immunol. 9, 1963 (2018).","journal-title":"Front. Immunol."},{"key":"1294_CR45","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","volume":"586","author":"MJ Mulligan","year":"2020","unstructured":"Mulligan, M. J. et al. Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586, 589\u2013593 (2020).","journal-title":"Nature"},{"key":"1294_CR46","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh, E. E. et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N. Engl. J. Med. 383, 2439\u20132450 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1294_CR47","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00508-021-01922-y","volume":"133","author":"P Kremsner","year":"2021","unstructured":"Kremsner, P. et al. Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: a phase 1 randomized clinical trial. Wien Klin. Wochenschr. 133, 931\u2013941 (2021).","journal-title":"Wien Klin. Wochenschr."},{"key":"1294_CR48","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2\u2014preliminary report. N. Engl. J. Med. 383, 1920\u20131931 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1294_CR49","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41541-021-00324-5","volume":"6","author":"KV Kalnin","year":"2021","unstructured":"Kalnin, K.V., Plitnik, T. & Kishko, M. et al. Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models. NPJ Vaccines 6, 61 (2021).","journal-title":"NPJ Vaccines"},{"key":"1294_CR50","doi-asserted-by":"crossref","unstructured":"Aliprantis, A. O. et al. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Hum. Vaccin. Immunother. 17, 1248\u20131261 (2020).","DOI":"10.1080\/21645515.2020.1829899"},{"key":"1294_CR51","unstructured":"Moderna. First Vaccines Day https:\/\/investors.modernatx.com\/events-and-presentations\/events\/event-details\/2020\/Vaccine-Day\/default.aspx (2020)."},{"key":"1294_CR52","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.3390\/jcm9051473","volume":"9","author":"U Kalathiya","year":"2020","unstructured":"Kalathiya, U. et al. Highly conserved homotrimer cavity formed by the SARS-CoV-2 spike glycoprotein: a novel binding site. J. Clin. Med. 9, 1473 (2020).","journal-title":"J. Clin. Med."},{"key":"1294_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-1111-6","volume":"15","author":"DK Edwards","year":"2017","unstructured":"Edwards, D. K. et al. Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response. J. Transl. Med. 15, 1 (2017).","journal-title":"J. Transl. Med."},{"key":"1294_CR54","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.4049\/jimmunol.165.8.4710","volume":"165","author":"D Weissman","year":"2000","unstructured":"Weissman, D. et al. HIV Gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. J. Immunol. 165, 4710\u20134717 (2000).","journal-title":"J. Immunol."},{"key":"1294_CR55","doi-asserted-by":"crossref","unstructured":"Lutz, J. et al. Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines 2, 29 (2017).","DOI":"10.1038\/s41541-017-0032-6"},{"key":"1294_CR56","doi-asserted-by":"publisher","first-page":"5884","DOI":"10.1093\/nar\/gkq347","volume":"38","author":"BR Anderson","year":"2010","unstructured":"Anderson, B. R. et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 38, 5884\u20135892 (2010).","journal-title":"Nucleic Acids Res."},{"key":"1294_CR57","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Karik\u00f3","year":"2005","unstructured":"Karik\u00f3, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165\u2013175 (2005).","journal-title":"Immunity"},{"key":"1294_CR58","unstructured":"World Health Organization. Messenger RNA Encoding the Full-Length SARS-CoV-2 Spike Glycoprotein https:\/\/berthub.eu\/articles\/11889.doc (2020)."},{"key":"1294_CR59","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.biomaterials.2016.09.006","volume":"109","author":"KJ Kauffman","year":"2016","unstructured":"Kauffman, K. J. et al. Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo. Biomaterials 109, 78\u201387 (2016).","journal-title":"Biomaterials"},{"key":"1294_CR60","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1093\/nar\/gkr695","volume":"39","author":"K Kariko","year":"2011","unstructured":"Kariko, K., Muramatsu, H., Ludwig, J. & Weissman, D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 39, e142 (2011).","journal-title":"Nucleic Acids Res."},{"key":"1294_CR61","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","volume":"15","author":"M Baiersd\u00f6rfer","year":"2019","unstructured":"Baiersd\u00f6rfer, M. et al. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids 15, 26\u201335 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1294_CR62","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","volume":"23","author":"S Tahtinen","year":"2022","unstructured":"Tahtinen, S. et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat. Immunol. 23, 532\u2013542 (2022).","journal-title":"Nat. Immunol."},{"key":"1294_CR63","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","volume":"390","author":"M Alberer","year":"2017","unstructured":"Alberer, M. et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 390, 1511\u20131520 (2017).","journal-title":"Lancet"},{"key":"1294_CR64","unstructured":"CureVac. CureVac B.V. Securities and Exchange Commission Filing https:\/\/sec.report\/Document\/0001104659-20-086354\/tm2016252-11_f1.htm (2020)."},{"key":"1294_CR65","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/jcph.1553","volume":"60","author":"X Zhang","year":"2019","unstructured":"Zhang, X., Goel, V. & Robbie, G. J. Pharmacokinetics of patisiran, the first approved RNA interference therapy in patients with hereditary transthyretin-mediated amyloidosis. J. Clin. Pharmacol. 60, 573\u2013585 (2019).","journal-title":"J. Clin. Pharmacol."},{"key":"1294_CR66","unstructured":"BioNTech. Update on COVID-19 Vaccine Program https:\/\/investors.biontech.de\/events\/event-details\/update-covid-19-vaccine-program-press-conference-0 (2020)."},{"key":"1294_CR67","unstructured":"Moderna. Annual R&D Day https:\/\/investors.modernatx.com\/events-and-presentations\/events\/event-details\/2020\/RD-Day\/default.aspx (2020)."},{"key":"1294_CR68","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nbt1402","volume":"26","author":"A Akinc","year":"2008","unstructured":"Akinc, A. et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26, 561\u2013569 (2008).","journal-title":"Nat. Biotechnol."},{"key":"1294_CR69","doi-asserted-by":"crossref","unstructured":"Love, K. T. et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl Acad. Sci. USA 107, 1864\u20131869 (2010).","DOI":"10.1073\/pnas.0910603106"},{"key":"1294_CR70","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1073\/pnas.1322937111","volume":"111","author":"Y Dong","year":"2014","unstructured":"Dong, Y. et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc. Natl Acad. Sci. USA 111, 3955\u20133960 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1294_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5277","volume":"5","author":"KA Whitehead","year":"2014","unstructured":"Whitehead, K. A. et al. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat. Commun. 5, 4277 (2014).","journal-title":"Nat. Commun."},{"key":"1294_CR72","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1002\/adma.201505822","volume":"28","author":"OS Fenton","year":"2016","unstructured":"Fenton, O. S. et al. Bioinspired alkenyl amino alcohol ionizable lipid materials for highly potent in vivo mRNA delivery. Adv. Mater. 28, 2939\u20132943 (2016).","journal-title":"Adv. Mater."},{"key":"1294_CR73","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/mt.2013.124","volume":"21","author":"MA Maier","year":"2013","unstructured":"Maier, M. A. et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21, 1570\u20131578 (2013).","journal-title":"Mol. Ther."},{"key":"1294_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","volume":"15","author":"KJ Hassett","year":"2019","unstructured":"Hassett, K. J. et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol. Ther. Nucleic Acids 15, 1\u201311 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1294_CR75","doi-asserted-by":"crossref","unstructured":"Nabhan, J. F. et al. Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich\u2019s ataxia. Sci. Rep. 6, 20019 (2016).","DOI":"10.1038\/srep20019"},{"key":"1294_CR76","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jconrel.2019.04.015","volume":"303","author":"S Patel","year":"2019","unstructured":"Patel, S., Ryals, R. C., Weller, K. K., Pennesi, M. E. & Sahay, G. Lipid nanoparticles for delivery of messenger RNA to the back of the eye. J. Control. Release 303, 91\u2013100 (2019).","journal-title":"J. Control. Release"},{"key":"1294_CR77","doi-asserted-by":"crossref","unstructured":"Lewin, A. S. et al. The effects of PEGylation on LNP based mRNA delivery to the eye. PLoS ONE 15, e0241006 (2020).","DOI":"10.1371\/journal.pone.0241006"},{"key":"1294_CR78","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/mt.2015.193","volume":"24","author":"IC Turnbull","year":"2016","unstructured":"Turnbull, I. C. et al. Myocardial delivery of lipidoid nanoparticle carrying modRNA induces rapid and transient expression. Mol. Ther. 24, 66\u201375 (2016).","journal-title":"Mol. Ther."},{"key":"1294_CR79","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.omtm.2020.05.030","volume":"18","author":"V Anttila","year":"2020","unstructured":"Anttila, V. et al. Synthetic mRNA encoding VEGF-A in patients undergoing coronary artery bypass grafting: design of a phase 2a clinical trial. Mol. Ther. Methods Clin. Dev. 18, 464\u2013472 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1294_CR80","doi-asserted-by":"crossref","unstructured":"Sahu, I., Haque, A. K. M. A., Weidensee, B., Weinmann, P. & Kormann, M. S. D. Recent developments in mRNA-based protein supplementation therapy to target lung diseases. Mol. Ther. 27, 803\u2013823 (2019).","DOI":"10.1016\/j.ymthe.2019.02.019"},{"key":"1294_CR81","doi-asserted-by":"publisher","first-page":"e1805116","DOI":"10.1002\/adma.201805116","volume":"31","author":"AK Patel","year":"2019","unstructured":"Patel, A. K. et al. Inhaled nanoformulated mRNA polyplexes for protein production in lung epithelium. Adv. Mater. 31, e1805116 (2019).","journal-title":"Adv. Mater."},{"key":"1294_CR82","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41551-021-00786-x","volume":"5","author":"MP Lokugamage","year":"2021","unstructured":"Lokugamage, M. P. et al. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nat. Biomed. Eng. 5, 1059\u20131068 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"1294_CR83","unstructured":"DeRosa, F., Heartlein, M. & Karve, S. Ice-Based Lipid Nanoparticle Formulation for Delivery of mRNA https:\/\/patents.google.com\/patent\/US20200155691A1\/ (2020)."},{"key":"1294_CR84","unstructured":"CureVac. CureVac\u2019s COVID-19 Vaccine Candidate, CVnCoV, Suitable for Standard Fridge Temperature Logistics https:\/\/www.curevac.com\/en\/2020\/11\/12\/curevacs-covid-19-vaccine-candidate-cvncov-suitable-for-standard-fridge-temperature-logistics\/ (2020)."},{"key":"1294_CR85","unstructured":"Moderna. Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures https:\/\/investors.modernatx.com\/news\/news-details\/2020\/Moderna-Announces-Longer-Shelf-Life-for-its-COVID-19-Vaccine-Candidate-at-Refrigerated-Temperatures-11-16-2020\/default.aspx (2020)."},{"key":"1294_CR86","unstructured":"US FDA. Coronavirus (COVID-19) Update: FDA Allows More Flexible Storage, Transportation Conditions for Pfizer\u2013BioNTech COVID-19 Vaccine https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-allows-more-flexible-storage-transportation-conditions-pfizer#:~:text=Today%2C%20the%20U.S.%20Food%20and,of%20up%20to%20two%20weeks (2021)."},{"key":"1294_CR87","unstructured":"Pfizer. Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-submit-covid-19-vaccine-stability-data (2021)."},{"key":"1294_CR88","unstructured":"Moderna. Moderna Provides Mid-Year Corporate Update https:\/\/investors.modernatx.com\/news\/news-details\/2018\/Moderna-Provides-Mid-Year-Corporate-Update-07-11-2018\/default.aspx (2018)."},{"key":"1294_CR89","unstructured":"Moderna, Inc. United States Securities and Exchange Commission Form S-1 (2018)."},{"key":"1294_CR90","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.bioactmat.2020.03.001","volume":"5","author":"P Zhao","year":"2020","unstructured":"Zhao, P. et al. Long-term storage of lipid-like nanoparticles for mRNA delivery. Bioact. Mater. 5, 358\u2013363 (2020).","journal-title":"Bioact. Mater."},{"key":"1294_CR91","doi-asserted-by":"crossref","unstructured":"Crommelin, D. J. A., Anchordoquy, T. J., Volkin, D. B., Jiskoot, W. & Mastrobattista, E. Addressing the cold reality of mRNA vaccine stability. J. Pharm. Sci. 110, 997\u20131001 (2020).","DOI":"10.1016\/j.xphs.2020.12.006"},{"key":"1294_CR92","unstructured":"O\u2019Hare, R. Landmark coronavirus study to trial inhaled Imperial and Oxford vaccines. Imperial News Imperial College London https:\/\/www.imperial.ac.uk\/news\/203653\/landmark-coronavirus-study-trial-inhaled-imperial\/ (14 September 2020)."},{"key":"1294_CR93","doi-asserted-by":"crossref","unstructured":"Wang, Z. et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci. Transl. Med. 13, eabf1555 (2021).","DOI":"10.1126\/scitranslmed.abf1555"},{"key":"1294_CR94","doi-asserted-by":"crossref","unstructured":"Pizzolla, A. et al. Resident memory CD8+ T cells in the upper respiratory tract prevent pulmonary influenza virus infection. Sci. Immunol. 2, eaam6970 (2017).","DOI":"10.1126\/sciimmunol.aam6970"},{"key":"1294_CR95","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41590-018-0260-6","volume":"20","author":"SR Allie","year":"2018","unstructured":"Allie, S. R. et al. The establishment of resident memory B cells in the lung requires local antigen encounter. Nat. Immunol. 20, 97\u2013108 (2018).","journal-title":"Nat. Immunol."},{"key":"1294_CR96","doi-asserted-by":"crossref","unstructured":"Lorenzi, J. C. C. et al. Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosis. BMC Biotechnology 10, 77 (2010).","DOI":"10.1186\/1472-6750-10-77"},{"key":"1294_CR97","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","volume":"37","author":"RA Feldman","year":"2019","unstructured":"Feldman, R. A. et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine 37, 3326\u20133334 (2019).","journal-title":"Vaccine"},{"key":"1294_CR98","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1097\/QAD.0000000000002026","volume":"32","author":"L Leal","year":"2018","unstructured":"Leal, L. et al. Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection. AIDS 32, 2533\u20132545 (2018).","journal-title":"AIDS"},{"key":"1294_CR99","unstructured":"Thomas, K. U.S. COVID vaccine supply: how to make sense of those confusing numbers. The New York Times https:\/\/www.nytimes.com\/2021\/01\/21\/health\/covid-vaccine-supply-biden.html (21 January 2021)."},{"key":"1294_CR100","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41541-022-00432-w","volume":"7","author":"H Parry","year":"2022","unstructured":"Parry, H. et al. Extended interval BNT162b2 vaccination enhances peak antibody generation. NPJ Vaccines 7, 14 (2022).","journal-title":"NPJ Vaccines"},{"key":"1294_CR101","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","volume":"385","author":"SJ Thomas","year":"2021","unstructured":"Thomas, S. J. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. N. Engl. J. Med. 385, 1761\u20131773 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1294_CR102","unstructured":"Moderna. Moderna Announces Advances Across Its Industry Leading mRNA Pipeline and Provides Business Update https:\/\/investors.modernatx.com\/news\/news-details\/2022\/Moderna-Announces-Advances-Across-Its-Industry-Leading-mRNA-Pipeline-and-Provides-Business-Update-01-10-2022\/default.aspx (2022)."},{"key":"1294_CR103","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1294_CR104","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1294_CR105","unstructured":"Pfizer. Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine (2020)."},{"key":"1294_CR106","unstructured":"CureVac. CureVac Commences Global Pivotal Phase 2b\/3 Trial for COVID-19 Vaccine Candidate, CVnCoV https:\/\/www.curevac.com\/en\/2020\/12\/14\/curevac-commences-global-pivotal-phase-2b-3-trial-for-covid-19-vaccine-candidate-cvncov\/ (2020)."},{"key":"1294_CR107","unstructured":"CureVac. CureVac Announces Positive Results in Low Dose\u20141\u2009\u03bcg\u2014Rabies Vaccine Clinical Phase 1 Study https:\/\/www.curevac.com\/en\/curevac-announces-positive-results-in-low-dose-1-%c2%b5g-rabies-vaccine-clinical-phase-1-study\/ (2020)."},{"key":"1294_CR108","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.vaccine.2019.02.024","volume":"37","author":"F Doener","year":"2019","unstructured":"Doener, F. et al. RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial. Vaccine 37, 1819\u20131826 (2019).","journal-title":"Vaccine"},{"key":"1294_CR109","doi-asserted-by":"crossref","unstructured":"Eigentler, T., Krauss, J. & Schriber, J. Intratumoral RNA-based TLR-7\/-8 and RIG-I agonist CV8102 alone and in combination with anti-PD-1 in a phase I dose-escalation and expansion trial in patients with advanced solid tumors. Cancer Res. 79, LB-021 (2019).","DOI":"10.1158\/1538-7445.AM2019-LB-021"},{"key":"1294_CR110","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.4161\/hv.25181","volume":"9","author":"KJ Kallen","year":"2013","unstructured":"Kallen, K. J. et al. A novel, disruptive vaccination technology: self-adjuvanted RNActive\u00ae vaccines. Hum. Vaccin. Immunother. 9, 2263\u20132276 (2013).","journal-title":"Hum. Vaccin. Immunother."},{"key":"1294_CR111","doi-asserted-by":"crossref","unstructured":"Rauch, S., Lutz, J., Kowalczyk, A., Schlake, T. & Heidenreich, R. RNActive\u00ae technology: generation and testing of stable and immunogenic mRNA vaccines. Methods Mol. Biol. 1499, 89\u2013107 (2017).","DOI":"10.1007\/978-1-4939-6481-9_5"},{"key":"1294_CR112","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3940-0","volume":"20","author":"W de Jong","year":"2019","unstructured":"de Jong, W. et al. Correction to: iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. Trials 20, 721 (2019).","journal-title":"Trials"},{"key":"1294_CR113","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3409-1","volume":"20","author":"W de Jong","year":"2019","unstructured":"de Jong, W. et al. iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. Trials 20, 361 (2019).","journal-title":"Trials"},{"key":"1294_CR114","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/s41587-019-0247-3","volume":"37","author":"L Miao","year":"2019","unstructured":"Miao, L. et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat. Biotechnol. 37, 1174\u20131185 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1294_CR115","doi-asserted-by":"publisher","first-page":"977","DOI":"10.15585\/mmwr.mm7027e2","volume":"70","author":"JW Gargano","year":"2021","unstructured":"Gargano, J. W. et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices\u2014United States, June 2021. Morb. Mortal. Wkly Rep. 70, 977\u2013982 (2021).","journal-title":"Morb. Mortal. Wkly Rep."},{"key":"1294_CR116","doi-asserted-by":"publisher","first-page":"118110","DOI":"10.1016\/j.lfs.2020.118110","volume":"258","author":"K Mortezaee","year":"2020","unstructured":"Mortezaee, K. Immune escape: a critical hallmark in solid tumors. Life Sci. 258, 118110 (2020).","journal-title":"Life Sci."},{"key":"1294_CR117","doi-asserted-by":"publisher","first-page":"6176","DOI":"10.3390\/ijms21176176","volume":"21","author":"Y Haibe","year":"2020","unstructured":"Haibe, Y., El Husseini, Z., El Sayed, R. & Shamseddine, A. Resisting resistance to immune checkpoint therapy: a systematic review. Int. J. Mol. Sci. 21, 6176 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1294_CR118","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/s41591-019-0596-y","volume":"25","author":"TN Yamamoto","year":"2019","unstructured":"Yamamoto, T. N., Kishton, R. J. & Restifo, N. P. Developing neoantigen-targeted T cell-based treatments for solid tumors. Nat. Med. 25, 1488\u20131499 (2019).","journal-title":"Nat. Med."},{"key":"1294_CR119","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass, E. & Ott, P. A. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 18, 215\u2013229 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1294_CR120","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13046-018-0751-1","volume":"37","author":"L Aurisicchio","year":"2018","unstructured":"Aurisicchio, L., Pallocca, M., Ciliberto, G. & Palombo, F. The perfect personalized cancer therapy: cancer vaccines against neoantigens. J. Exp. Clin. Cancer Res. 37, 86 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1294_CR121","doi-asserted-by":"publisher","first-page":"1912892","DOI":"10.1080\/2162402X.2021.1912892","volume":"10","author":"CD Zahm","year":"2021","unstructured":"Zahm, C. D., Moseman, J. E., Delmastro, L. E. & Mcneel, D. G. PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy. Oncoimmunology 10, 1912892 (2021).","journal-title":"Oncoimmunology"},{"key":"1294_CR122","unstructured":"BioNTech SE. United States Securities and Exchange Commission Form F-1 https:\/\/investors.biontech.de\/node\/8126\/html (2020)."},{"key":"1294_CR123","doi-asserted-by":"publisher","first-page":"109997","DOI":"10.1016\/j.biopha.2020.109997","volume":"125","author":"X Liang","year":"2020","unstructured":"Liang, X., Li, D., Leng, S. & Zhu, X. RNA-based pharmacotherapy for tumors: from bench to clinic and back. Biomed. Pharmacother. 125, 109997 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"1294_CR124","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/pharmaceutics12020102","volume":"12","author":"A Wadhwa","year":"2020","unstructured":"Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C. & Thakur, A. Opportunities and challenges in the delivery of mRNA-based vaccines. Pharmaceutics 12, 102 (2020).","journal-title":"Pharmaceutics"},{"key":"1294_CR125","doi-asserted-by":"publisher","first-page":"102859","DOI":"10.1016\/j.critrevonc.2019.102859","volume":"146","author":"I Giopanou","year":"2020","unstructured":"Giopanou, I. & Pintzas, A. RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: similarities and main differences for prognosis and therapies. Crit. Rev. Oncol. Hematol. 146, 102859 (2020).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1294_CR126","unstructured":"BioNTech. Next Generation Immunotherapy https:\/\/biontechse.gcs-web.com\/static-files\/b5a97ca9-efe5-485b-838c-940989ce8352 (2020)."},{"key":"1294_CR127","unstructured":"Sahin, U. et al. Mutanome Engineered RNA Immunotherapy (MERIT). Eur. Comm. Proj. Summ. https:\/\/www.liebertpub.com\/doi\/pdfplus\/10.1089\/humc.2015.2524 (2015)."},{"key":"1294_CR128","unstructured":"BioNTech. Securities and Exchange Commission Filing https:\/\/www.sec.gov\/Archives\/edgar\/data\/1776985\/000119312520022991\/d838504df1.htm (2020)."},{"key":"1294_CR129","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/CJI.0b013e31815ce501","volume":"31","author":"B Weide","year":"2008","unstructured":"Weide, B. et al. Results of the first phase I\/II clinical vaccination trial with direct injection of mRNA. J. Immunother. 31, 180\u2013188 (2008).","journal-title":"J. Immunother."},{"key":"1294_CR130","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/mt.2010.289","volume":"19","author":"SM Rittig","year":"2011","unstructured":"Rittig, S. M. et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol. Ther. 19, 990\u2013999 (2011).","journal-title":"Mol. Ther."},{"key":"1294_CR131","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/CJI.0b013e3181a00068","volume":"32","author":"B Weide","year":"2009","unstructured":"Weide, B. et al. Direct injection of protamine-protected mRNA: results of a phase 1\/2 vaccination trial in metastatic melanoma patients. J. Immunother. 32, 498\u2013507 (2009).","journal-title":"J. Immunother."},{"key":"1294_CR132","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40425-015-0068-y","volume":"3","author":"H Kubler","year":"2015","unstructured":"Kubler, H. et al. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I\/IIa study. J. Immunother. Cancer 3, 26 (2015).","journal-title":"J. Immunother. Cancer"},{"key":"1294_CR133","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.4161\/hv.29553","volume":"10","author":"S Rausch","year":"2014","unstructured":"Rausch, S., Schwentner, C., Stenzl, A. & Bedke, J. mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer. Hum. Vaccin. Immunother. 10, 3146\u20133152 (2014).","journal-title":"Hum. Vaccin. Immunother."},{"key":"1294_CR134","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00262-019-02315-x","volume":"68","author":"M Sebastian","year":"2019","unstructured":"Sebastian, M. et al. A phase I\/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB\/IV non-small cell lung cancer. Cancer Immunol. Immunother. 68, 799\u2013812 (2019).","journal-title":"Cancer Immunol. Immunother."},{"key":"1294_CR135","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40425-019-0520-5","volume":"7","author":"A Papachristofilou","year":"2019","unstructured":"Papachristofilou, A. et al. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J. Immunother. Cancer 7, 38 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1294_CR136","doi-asserted-by":"crossref","unstructured":"Gandhi, L. et al. Phase 1\/2 study of mRNA vaccine therapy\u2009+\u2009durvalumab (durva)\u2009\u00b1\u2009tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. 36, TPS9107 (2018).","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS9107"},{"key":"1294_CR137","doi-asserted-by":"crossref","unstructured":"Sabari, J. et al. Phase 1\/2 study of mRNA vaccine therapy\u2009+\u2009durvalumab (durva)\u2009\u00b1\u2009tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC). Cancer Immunol. Res. 7, B209 (2019).","DOI":"10.1158\/2326-6074.CRICIMTEATIAACR18-B209"},{"key":"1294_CR138","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","volume":"183","author":"DK Wells","year":"2020","unstructured":"Wells, D. K. et al. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell 183, 818\u2013834 (2020).","journal-title":"Cell"},{"key":"1294_CR139","doi-asserted-by":"crossref","unstructured":"Esprit, A. et al. Neo-antigen mRNA vaccines. Vaccines 8, 776 (2020).","DOI":"10.3390\/vaccines8040776"},{"key":"1294_CR140","doi-asserted-by":"publisher","first-page":"1029\u20131041","DOI":"10.1056\/NEJMra1615896","volume":"378","author":"R Yarchoan","year":"2018","unstructured":"Yarchoan, R. & Uldrick, T. S. HIV-associated cancers and related diseases. N. Engl. J. Med. 378, 1029\u20131041 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1294_CR141","doi-asserted-by":"publisher","first-page":"113","DOI":"10.21775\/cimb.022.113","volume":"22","author":"M Diken","year":"2017","unstructured":"Diken, M., Kranz, L. M., Kreiter, S. & Sahin, U. mRNA: a versatile molecule for cancer vaccines. Curr. Issues Mol. Biol. 22, 113\u2013128 (2017).","journal-title":"Curr. Issues Mol. Biol."},{"key":"1294_CR142","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222\u2013226 (2017).","journal-title":"Nature"},{"key":"1294_CR143","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/mt.2010.85","volume":"18","author":"A Akinc","year":"2010","unstructured":"Akinc, A. et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357\u20131364 (2010).","journal-title":"Mol. Ther."},{"key":"1294_CR144","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing. Nat. Nanotechnol. 15, 313\u2013320 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"1294_CR145","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","volume":"534","author":"LM Kranz","year":"2016","unstructured":"Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396\u2013401 (2016).","journal-title":"Nature"},{"key":"1294_CR146","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41551-020-00623-7","volume":"4","author":"M Krohn-Grimberghe","year":"2020","unstructured":"Krohn-Grimberghe, M. et al. Nanoparticle-encapsulated siRNAs for gene silencing in the haematopoietic stem-cell niche. Nat. Biomed. Eng. 4, 1076\u20131089 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"1294_CR147","unstructured":"Moderna. Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944) https:\/\/investors.modernatx.com\/news-releases\/news-release-details\/moderna-announces-positive-phase-1-results-first-systemic (2019)."},{"key":"1294_CR148","unstructured":"CureVac. Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics https:\/\/www.curevac.com\/news\/genmab-and-curevac-enter-strategic-partnership-to-develop-mrna-based-antibody-therapeutics (2019)."},{"key":"1294_CR149","unstructured":"Ethris. Neurimmune and Ethris Sign Collaboration Agreement to Rapidly Develop Inhaled mRNA-based Antibody Therapy for the Treatment of COVID-19 https:\/\/ethris.com\/wp-content\/uploads\/2020\/04\/20200401_Neurimmune_and_Ethris_sign_collaboration_agreement_final.pdf (2020)."},{"key":"1294_CR150","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1200\/JCO.2019.37.15_suppl.2641","volume":"37","author":"AMA Fernandez","year":"2019","unstructured":"Fernandez, A. M. A. et al. A phase I study (E011-MEL) of a TriMix-based mRNA immunotherapy (ECI-006) in resected melanoma patients: analysis of safety and immunogenicity. J. Clin. Oncol. 37, 2641 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1294_CR151","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1158\/1078-0432.CCR-19-3642","volume":"26","author":"WX Hong","year":"2020","unstructured":"Hong, W. X. et al. Intratumoral immunotherapy for early-stage solid tumors. Clin. Cancer Res. 26, 3091\u20133099 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1294_CR152","unstructured":"National Cancer Institute. CAR T Cells: Engineering Patients\u2019 Immune Cells to Treat Their Cancers https:\/\/www.cancer.gov\/about-cancer\/treatment\/research\/car-t-cells (2019)."},{"key":"1294_CR153","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","volume":"5","author":"J Tchou","year":"2017","unstructured":"Tchou, J. et al. Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunol. Res. 5, 1152\u20131161 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"1294_CR154","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","volume":"1","author":"MV Maus","year":"2013","unstructured":"Maus, M. V. et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol. Res. 1, 26\u201331 (2013).","journal-title":"Cancer Immunol. Res."},{"key":"1294_CR155","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","volume":"155","author":"GL Beatty","year":"2018","unstructured":"Beatty, G. L. et al. Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology 155, 29\u201332 (2018).","journal-title":"Gastroenterology"},{"key":"1294_CR156","doi-asserted-by":"crossref","unstructured":"Parayath, N. N., Stephan, S. B., Koehne, A. L., Nelson, P. S. & Stephan, M. T. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat. Commun. 11, 6080 (2020).","DOI":"10.1038\/s41467-020-19486-2"},{"key":"1294_CR157","doi-asserted-by":"crossref","unstructured":"Zhang, F. et al. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat. Commun. 10, 3974 (2019).","DOI":"10.1038\/s41467-019-11911-5"},{"key":"1294_CR158","doi-asserted-by":"crossref","unstructured":"Fenton, O. S. et al. Synthesis and biological evaluation of ionizable lipid materials for the in vivo delivery of messenger RNA to B lymphocytes. Adv. Mater. 29, 1606944 (2017).","DOI":"10.1002\/adma.201606944"},{"key":"1294_CR159","doi-asserted-by":"publisher","first-page":"E5859","DOI":"10.1073\/pnas.1805358115","volume":"115","author":"CJ McKinlay","year":"2018","unstructured":"McKinlay, C. J., Benner, N. L., Haabeth, O. A., Waymouth, R. M. & Wender, P. A. Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters. Proc. Natl Acad. Sci. USA 115, E5859\u2013E5866 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1294_CR160","doi-asserted-by":"crossref","unstructured":"Lokugamage, M. P., Sago, C. D., Gan, Z., Krupczak, B. R. & Dahlman, J. E. Constrained nanoparticles deliver siRNA and sgRNA to T cells in vivo without targeting ligands. Adv. Mater. 31, 1902251 (2019).","DOI":"10.1002\/adma.201902251"},{"key":"1294_CR161","doi-asserted-by":"publisher","first-page":"20083","DOI":"10.1002\/anie.202008082","volume":"59","author":"X Zhao","year":"2020","unstructured":"Zhao, X. et al. Imidazole\u2010based synthetic lipidoids for in vivo mRNA delivery into primary T lymphocytes. Angew. Chem. Int. Ed. Engl. 59, 20083\u201320089 (2020).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"1294_CR162","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1016\/j.ymthe.2021.06.004","volume":"29","author":"I Tomb\u00e1cz","year":"2021","unstructured":"Tomb\u00e1cz, I. et al. Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA\u2013LNPs. Mol. Ther. 29, 3293\u20133304 (2021).","journal-title":"Mol. Ther."},{"key":"1294_CR163","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore, J. D. et al. CRISPR\u2013Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 385, 493\u2013502 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1294_CR164","unstructured":"Moderna. Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates https:\/\/investors.modernatx.com\/news\/news-details\/2021\/Moderna-Reports-Second-Quarter-Fiscal-Year-2021-Financial-Results-and-Provides-Business-Updates-08-05-2021\/default.aspx (2021)."},{"key":"1294_CR165","unstructured":"Moderna. Moderna Announces First Participant Dosed in Phase 1\/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine https:\/\/investors.modernatx.com\/news-releases\/news-release-details\/moderna-announces-first-participant-dosed-phase-12-study-its (2021)."}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41587-022-01294-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-022-01294-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-022-01294-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T14:14:51Z","timestamp":1675520091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41587-022-01294-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":165,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1294"],"URL":"https:\/\/doi.org\/10.1038\/s41587-022-01294-2","relation":{},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,9]]},"assertion":[{"value":"2 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.J.B. and R.W. are former employees of Translate Bio. D.G.A. is a consultant for Translate Bio. D.G.A is also a founder of oRNA Tx.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}